Clinical practice and metabolic consequences of olanzapine use in schizophrenia: results from a national survey in Spain L.I. Muñoz-Manchado; M. Bernardo; J.M. Villagrán-Moreno; E. Fernández-Egea;

Prevalence and risk factors of anxiety symptoms in first-episode and drug-naïve major depressive disorder patients with metabolic syndrome Jizhou Liu; Yonglan Yang; Yanjiang Zhang; Haifeng Wang; Wenjian Wei; Xiaoe Lang; Xiangyang Zhang;

Bipolar disorder and type 2 diabetes mellitus: A bidirectional relationship Dagmar Breznoscakova; Maria Pallayova;